www.urologiepropraxi.cz / Urol. praxi. 2025;26(2):65-69 / UROLOGIE PRO PRAXI 69 PŘEHLEDOVÉ ČLÁNKY Personalizovaná farmakoterapie mLUTS – efektivní přístup k ovlivnění symptomů OAB, zachování sexuálních funkcí a zlepšení kvality života 9. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-1314; discussion 1314-1315. 10. Kakizaki H, Lee KS, Yamamoto O, et al. Mirabegron Add- -on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus. 2020;6(4):729-737. 11. Gacci M, Sebastianelli A, Salvi M, et al. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015;16(9):60. 12. van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64(6):1003-1012. 13. Lenfant L, Pinar U, Roupret M, et al. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol. 2023;209(2):314-324. 14. Pang R, Zhou XY, Wang X, et al. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction. Cochrane Database Syst Rev. 2021;2(2):CD012336. 15. Drake MJ, Oelke M, Snijder R, et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PLoS One. 2017;12(2):e0170726. 16. Kim HJ, Sun HY, Choi H, et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PLoS One. 2017;12(1):e0169248. 17. Krhut J, Ryšánková K, Zachoval R. Nežádoucí účinky anticholinergik užívaných v léčbě hyperaktivního močového měchýře na centrální nervový systém. Ces Urol. 2024; 28(3):133-140. 18. Kaplan SA, Herschorn S, McVary KT, et al. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J Urol. 2020;203(6):1163-1171. 19. Soliman MG, El-Abd SA, Tawfik AM, et al. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO. World J Urol. 2021;39(6):2049-2054. 20. Hoffman V, Hallas J, Linder M, et al. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. 2021;44(8):899-915. 21. Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60(4):809-825. 22. Sebastianelli A, Spatafora P, Morselli S, et al. Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED. Curr Urol Rep. 2020;21(12):56. 23. Mondul AM, Giovannucci E, Platz EA. A Prospective Study of Physical Activity, Sedentary Behavior, and Incidence and Progression of Lower Urinary Tract Symptoms. J Gen Intern Med. 2020;35(8):2281-2288. ODBORNÝ GARANT: MUDr. Igor Hartmann, Ph.D. POŘADATEL: SOLEN, s. r. o., ve spolupráci s Urologickou klinikou, Fakultní nemocnice Olomouc PARTNEŘI POČET KREDITŮ 2 Registrace ZDARMA TERMÍN srpen 2024 až červenec 2025 dostupný na online.solen.cz ON LINE KURZ OBSAH KURZU Hormonálně senzitivní karcinom prostaty MUDr. Milan Král, Ph.D. Mirabegron v léčbě hyperaktivního močového měchýře – mýty a fakta MUDr. Eva Burešová, Ph.D., doc. MUDr. Aleš Vidlář, Ph.D. Systémová léčba karcinomu ledviny doc. MUDr. Hana Študentová, Ph.D. Léčba kastračně rezistentního karcinomu prostaty MUDr. Hana Perková Urologie pro praxi
RkJQdWJsaXNoZXIy NDA4Mjc=